

- Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74–108.
- Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated non-surgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology* 1999;29:62–67.
- Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. *Lancet* 2014;383:515–523.
- Yu MW, Yang YC, Yang SY, et al. Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women. *Hepatology* 2002;36:156–163.
- Kim WR, Gores GJ, Benson JT, et al. Mortality and hospital utilization for hepatocellular carcinoma in the United States. *Gastroenterology* 2005;129:486–493.
- Chang MH, Chen TH, Hsu HM, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. *Clin Cancer Res* 2005;11:7953–7957.
- Stiegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
- Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. *Lancet* 1981;2:1129–1133.
- Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. *J Hepatol* 2009;50:80–88.
- Blum HE, Moradpour D. Viral pathogenesis of hepatocellular carcinoma. *J Gastroenterol Hepatol* 2002;17:S413–S420.
- Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. *Nat Rev Cancer* 2006;6:674–687.
- Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. *Nat Rev Immunol* 2005;5:215–229.
- Hoshida Y, Toffanin S, Lachenmayer A, et al. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. *Semin Liver Dis* 2010;30:35–51.
- Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. *Semin Liver Dis* 2007;27:55–76.
- Zhang Y, Wei W, Cheng N, et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. *Hepatology* 2012;56:1631–1640.
- Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. *Biol Chem* 2006;387:349–360.
- McClain CJ, Hill DB, Song Z, et al. Monocyte activation in alcoholic liver disease. *Alcohol* 2002;27:53–61.
- Osna NA, Clemens DL, Donohue TM Jr. Ethanol metabolism alters interferon gamma signaling in recombinant HepG2 cells. *Hepatology* 2005;42:1109–1117.
- Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004;40:1387–1395.
- Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. *Semin Liver Dis* 2008;28:339–350.
- Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 2011;140:124–131.
- Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *Hepatology* 2010;51:1972–1978.
- Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. *J Gastroenterol Hepatol* 2009;24:248–254.
- Ertle J, Dechene A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. *Int J Cancer* 2011;128:2436–2443.
- Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. *Hepatology* 2010;51:1820–1832.
- Regimbeau JM, Colombat M, Mognol P, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. *Liver Transpl* 2004;10:S69–S73.
- Guzman G, Brunt EM, Petrovic LM, et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? *Arch Pathol Lab Med* 2008;132:1761–1766.
- Gao J, Xie L, Yang WS, et al. Risk factors of hepatocellular carcinoma—current status and perspectives. *Asian Pac J Cancer Prev* 2012;13:743–752.
- Henderson BE, Preston-Martin S, Edmondson HA, et al. Hepatocellular carcinoma and oral contraceptives. *Br J Cancer* 1983;48:437–440.
- Ha NB, Ahmed A, Ayoub W, et al. Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case-control study. *Cancer Causes Control* 2012;23:455–462.
- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* 2010;17:1471–1474.
- Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973;60:646–649.
- A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. *Hepatology* 1998;28:751–755.
- Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. *Hepatology* 2000;31:840–845.
- Kaseb AO, Hassan MM, Lin E, et al. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. *Cancer* 2011;117:2478–2488.
- Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. *Cancer* 2002;94:1760–1769.
- Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. *J Hepatol* 1999;31:133–141.
- Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). *J Gastroenterol* 2003;38:207–215.
- Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 1999;19:329–338.
- Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. *J Hepatol* 2006;44:723–731.
- Collette S, Bonnetain F, Paoletti X, et al. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. *Ann Oncol* 2008;19:1117–1126.
- Huitzil-Melendez FD, Capanu M, O'Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? *J Clin Oncol* 2010;28:2889–2895.
- Dusenbery D, Ferris JV, Thaete FL, et al. Percutaneous ultrasound-guided needle biopsy of hepatic mass lesions using a cytohistologic approach. Comparison of two needle types. *Am J Clin Pathol* 1995;104:583–587.
- Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. *Hepatology* 2007;45:725–734.
- Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011;53:1020–1022.
- Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* 2001;35:421–430.
- Fornier A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. *Hepatology* 2008;47:97–104.
- Bialecki ES, Ezenekwe AM, Brunt EM, et al. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2006;4:361–368.
- Bret PM, Labadie M, Bretagnolle M, et al. Hepatocellular carcinoma: diagnosis by percutaneous fine needle biopsy. *Gastrointest Radiol* 1988;13:253–255.
- Durand F, Regimbeau JM, Belghiti J, et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. *J Hepatol* 2001;35:254–258.
- Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver transplantation. *N Engl J Med* 2007;356:1545–1559.
- Capussotti L, Ferrero A, Vigano L, et al. Liver resection for HCC with cirrhosis: surgical perspectives out of EASL/AASLD guidelines. *Eur J Surg Oncol* 2009;35:11–15.
- Cucchetti A, Erolani G, Vivarelli M, et al. Is portal hypertension a contraindication to hepatic resection? *Ann Surg* 2009;250:922–928.
- Shirabe K, Shimada M, Gion T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. *J Am Coll Surg* 1999;188:304–309.
- Breitenstein S, Apestegui C, Petrowsky H, et al. "State of the art" in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers. *World J Surg* 2009;33:797–803.
- Aoki T, Imamura H, Hasegawa K, et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. *Arch Surg* 2004;139:766–774.
- Ogata S, Belghiti J, Farges O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. *Br J Surg* 2006;93:1091–1098.
- Palavecino M, Chun YS, Madoff DC, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. *Surgery* 2009;145:399–405.

59. Seo DD, Lee HC, Jang MK, et al. Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization. *Ann Surg Oncol* 2007;14:3501–3509.
60. Fan ST, Lo CM, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. *Ann Surg* 1999;229:322–330.
61. Poon RT, Fan ST. Assessment of hepatic reserve for indication of hepatic resection: how I do it. *J Hepatobiliary Pancreat Surg* 2005;12:31–37.
62. Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. *Cancer* 1990;65:1104–1110.
63. Liu JH, Chen PW, Asch SM, et al. Surgery for hepatocellular carcinoma: does it improve survival? *Ann Surg Oncol* 2004;11:298–303.
64. Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for hepatocellular carcinoma in the elderly. *J Am Coll Surg* 2001;192:38–46.
65. Ercolani G, Grazi GL, Ravaoli M, et al. Liver resection for hepatocellular carcinoma in cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. *Ann Surg* 2003;237:536–543.
66. Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. *Cancer* 2001;91:1479–1486.
67. Belghiti J, Regimbeau JM, Durand F, et al. Resection of hepatocellular carcinoma: a European experience on 328 cases. *Hepatogastroenterology* 2002;49:41–46.
68. Kanematsu T, Furui J, Yanaga K, et al. A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985–2000. *Surgery* 2002;131:S153–S158.
69. Wayne JD, Lauwers GY, Ikai I, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. *Ann Surg* 2002;235:722–730.
70. Wu CC, Cheng SB, Ho WM, et al. Liver resection for hepatocellular carcinoma in patients with cirrhosis. *Br J Surg* 2005;92:348–355.
71. Capussotti L, Muratore A, Amisano M, et al. Liver resection for hepatocellular carcinoma in cirrhosis: analysis of mortality, morbidity and survival—a European single center experience. *Eur J Surg Oncol* 2005;31:986–993.
72. Hasegawa K, Kokudo N, Imamura H, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. *Ann Surg* 2005;242:252–259.
73. Nathan H, Schulick RD, Choti MA, et al. Predictors of survival after resection of early hepatocellular carcinoma. *Ann Surg* 2009;249:799–805.
74. Yang LY, Fang F, Ou DP, et al. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. *Ann Surg* 2009;249:118–123.
75. Wang J, Xu LB, Liu C, et al. Prognostic factors and outcome of 438 Chinese patients with hepatocellular carcinoma underwent partial hepatectomy in a single center. *World J Surg* 2010;34:2434–2441.
76. Lise M, Bacchetti S, Da Pian P, et al. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. *Cancer* 1998;82:1028–1036.
77. Shi M, Guo RP, Lin XJ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. *Ann Surg* 2007;245:36–43.
78. Ikai I, Arai S, Kojima M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. *Cancer* 2004;101:796–802.
79. Kang CM, Choi GH, Kim DH, et al. Revisiting the role of nonanatomic resection of small ( $\leq$  4 cm) and single hepatocellular carcinoma in patients with well-preserved liver function. *J Surg Res* 2010;160:81–89.
80. Bismuth H, Chiche L, Adam R, et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. *Ann Surg* 1993;218:145–151.
81. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996;334:693–699.
82. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. *Ann Surg* 2004;239:150–159.
83. Hemming AW, Cattral MS, Reed AI, et al. Liver transplantation for hepatocellular carcinoma. *Ann Surg* 2001;233:652–659.
84. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol* 2009;10:35–43.
85. Pelletier SJ, Fu S, Thyagarajan V, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. *Liver Transpl* 2009;15:859–868.
86. Herrero JL, Sangro B, Pardo F, et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. *Liver Transpl* 2008;14:272–278.
87. Onaca N, Davis GL, Goldstein RM, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. *Liver Transpl* 2007;13:391–399.
88. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. *Liver Transpl* 2006;12:1761–1769.
89. Bigourdan JM, Jaeck D, Meyer N, et al. Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation. *Liver Transpl* 2003;9:513–520.
90. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology* 2001;33:1394–1403.
91. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. *Arch Surg* 2001;136:25–30.
92. Regalia E, Coppa J, Pulvirenti A, et al. Liver transplantation for small hepatocellular carcinoma in cirrhosis: analysis of our experience. *Transplant Proc* 2001;33:1442–1444.
93. Jonas S, Herrmann M, Rayes N, et al. Survival after liver transplantation for hepatocellular carcinoma in cirrhosis according to the underlying liver disease. *Transplant Proc* 2001;33:3444–3445.
94. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. *Hepatology* 1998;27:1572–1577.
95. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. *Am J Transplant* 2007;7:2587–2596.
96. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. *Ann Surg* 2007;246:502–509.
97. Olthoff KM, Merion RM, Ghobrial RM, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the AZALL Consortium. *Ann Surg* 2005;242:314–323.
98. Sarasin FP, Majno PE, Llovet JM, et al. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. *Hepatology* 2001;33:1073–1079.
99. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. *Ann Surg* 2004;240:451–459.
100. Hwang S, Lee SC, Joh JW, et al. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. *Liver Transpl* 2005;11:1265–1272.
101. Takada Y, Ueda M, Ito T, et al. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. *Liver Transpl* 2006;12:912–919.
102. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. *Dig Dis* 2007;25:310–312.
103. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002;35:1164–1171.
104. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. *Hepatology* 1999;30:1434–1440.
105. Maddala YK, Stadheim L, Andrews JC, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. *Liver Transpl* 2004;10:449–455.
106. Vilana R, Bruix J, Bru C, et al. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. *Hepatology* 1992;16:353–357.
107. Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. *Radiology* 2005;234:954–960.
108. Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. *Ann Surg* 2004;240:900–909.
109. Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. *Ann Surg* 2007;245:831–842.
110. Chen LT, Chen MF, Li LA, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. *Ann Surg* 2012;255:8–17.
111. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. *Lancet* 1999;353:797–801.
112. Lau WY, Lai EC, Leung TW, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. *Ann Surg* 2008;247:43–48.
113. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. *N Engl J Med* 1996;334:1561–1567.
114. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. *N Engl J Med* 1999;340:1046–1047.
115. Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study. *Hepatol Res* 2014;44:523–531.

116. Wu CC, Ho YZ, Ho WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. *Br J Surg* 1995;82:122–126.
117. Schwartz JD, Schwartz M, Mandeli J, et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. *Lancet Oncol* 2002;3:593–603.
118. Yamasaki S, Hasegawa H, Kinoshita H, et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. *Jpn J Cancer Res* 1996;87:206–211.
119. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. *Ann Intern Med* 2003;138:299–306.
120. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower posturgical recurrence rates of hepatocellular carcinoma: a randomised trial. *Lancet* 2000;356:802–807.
121. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. *Hepatology* 2006;44:1543–1554.
122. Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. *Br J Surg* 2009;96:975–981.
123. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. *Clin Cancer Res* 1999;5:1676–1681.
124. Cherqui D, Laurent A, Mocellin N, et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. *Ann Surg* 2009;250:738–746.
125. Chua TC, Saxena A, Chu F, et al. Hepatic resection for transplantable hepatocellular carcinoma for patients within Milan and UCSF Criteria. *Am J Clin Oncol* 2012;35:141–145.
126. Margarit C, Escartin A, Castells L, et al. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. *Liver Transpl* 2005;11:1242–1251.
127. Lee KK, Kim DG, Moon IS, et al. Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. *J Surg Oncol* 2010;101:47–53.
128. Facciuto ME, Rochon C, Pandey M, et al. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. *HPB (Oxford)* 2009;11:398–404.
129. Del Caudio M, Ercolani G, Ravaoli M, et al. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. *Am J Transplant* 2008;8:1177–1185.
130. Shah SA, Cleary SP, Tan JC, et al. An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution. *Ann Surg Oncol* 2007;14:2608–2614.
131. Poon RT, Fan ST, Lo CM, et al. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. *Ann Surg* 2007;245:51–58.
132. Adam R, Azoulay D, Castaing D, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? *Ann Surg* 2003;238:508–518.
133. Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver transplantation for hepatocellular carcinoma. *Ann Surg* 2003;238:885–892.
134. Figueras J, Jaurieta E, Valls C, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. *J Am Coll Surg* 2000;190:580–587.
135. Cucchetti A, Vitale A, Gaudio MD, et al. Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. *Am J Transplant* 2010;10:619–627.
136. Belghiti J. Resection and liver transplantation for HCC. *J Gastroenterol* 2009;44:132–135.
137. Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. *Ann Surg* 2002;235:373–382.
138. Canter RJ, Patel SA, Kennedy T, et al. Comparative analysis of outcome in patients with hepatocellular carcinoma exceeding the Milan criteria treated with liver transplantation versus partial hepatectomy. *Am J Clin Oncol* 2010;34:466–471.
139. Shiina S, Tagawa K, Unuma T, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. *Cancer* 1991;68:1524–1530.
140. Ohnishi K, Ohyama N, Ito S, et al. Small hepatocellular carcinoma: treatment with US-guided intratumoral injection of acetic acid. *Radiology* 1994;193:747–752.
141. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. *Radiology* 1995;197:101–108.
142. Blendis L. Percutaneous ethanol ablation of small hepatocellular carcinomas: twenty years on. *Gastroenterology* 2006;130:280–282.
143. Mazzanti R, Arena U, Pantaleo P, et al. Survival and prognostic factors in patients with hepatocellular carcinoma treated by percutaneous ethanol injection: a 10-year experience. *Can J Gastroenterol* 2004;18:611–618.
144. Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. *Gut* 2005;54:1151–1156.
145. Tsai WL, Cheng JS, Lai KH, et al. Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma—a long-term follow-up study. *Aliment Pharmacol Ther* 2008;28:304–311.
146. Weis S, Franke A, Mossner J, et al. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. *Cochrane Database Syst Rev* 2013;12:CD003046.
147. Kurokouchi K, Watanabe S, Masaki T, et al. Combination therapy of percutaneous ethanol injection and radiofrequency ablation against hepatocellular carcinomas difficult to treat. *Int J Oncol* 2002;21:611–615.
148. Cha DI, Lee MW, Rhim H, et al. Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations. *Korean J Radiol* 2013;14:240–247.
149. McGahan JP, Browning PD, Brock JM, et al. Hepatic ablation using radiofrequency electrocautery. *Invest Radiol* 1990;25:267–270.
150. Rossi S, Fornari F, Pathies C, et al. Thermal lesions induced by 480 KHz localized current field in guinea pig and pig liver. *Tumori* 1990;76:54–57.
151. Buscarini L, Rossi S, Fornari F, et al. Laparoscopic ablation of liver adenoma by radiofrequency electrocautery. *Gastrointest Endosc* 1995;41:68–70.
152. Organ LW. Electrophysiologic principles of radiofrequency lesion making. *Appl Neurophysiol* 1976;39:69–76.
153. Nahum Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities—part I. *J Vasc Interv Radiol* 2001;12:1021–1032.
154. Siperstein AE, Berber E, Ballem N, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. *Ann Surg* 2007;246:559–565.
155. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. *Eur Radiol* 2009;19:1206–1213.
156. Machi J, Oishi AJ, Sumida K, et al. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. *Cancer J* 2006;12:318–326.
157. Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. *Radiographics* 2005;25:S69–S83.
158. Ward RC, Healey TT, Dupuy DE. Microwave ablation devices for interventional oncology. *Expert Rev Med Devices* 2013;10:225–238.
159. Pathak S, Jones R, Tang JM, et al. Ablative therapies for colorectal liver metastases: a systematic review. *Colorectal Dis* 2011;13:e252–e265.
160. Dodd GD 3rd, Dodd NA, Lanctot AC, et al. Effect of variation of portal venous blood flow on radiofrequency and microwave ablations in a blood-perfused bovine liver model. *Radiology* 2013;267:129–136.
161. Wright AS, Lee FT Jr, Mahvi DM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. *Ann Surg Oncol* 2003;10:275–283.
162. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. *Ann Surg Oncol* 2010;17:171–178.
163. Liang P, Yu J, Yu XL, et al. Percutaneous cooled-tip microwave ablation under ultrasound guidance for primary liver cancer: a multicentre analysis of 1363 treatment-naïve lesions in 1007 patients in China. *Gut* 2012;61:1100–1101.
164. Mulier S, Ni Y, Jamart J, et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. *Ann Surg* 2005;242:158–171.
165. Lu DS, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. *J Vasc Interv Radiol* 2003;14:1267–1274.
166. Schramm W, Yang D, Wood BJ, et al. Contribution of direct heating, thermal conduction and perfusion during radiofrequency and microwave ablation. *Open Biomed Eng J* 2007;1:47–52.
167. Kingham TP, Karkar AM, D'Angelica MI, et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. *J Am Coll Surg* 2012;215:379–387.
168. Poon RT, Ng KK, Lam CM, et al. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. *Ann Surg* 2004;239:441–449.
169. Cabibbo G, Maida M, Genco C, et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. *World J Hepatol* 2012;4:256–261.
170. Ruzzenente A, Guglielmi A, Sandri M, et al. Surgical resection versus local ablation for HCC on cirrhosis: results from a propensity case-matched study. *J Gastrointest Surg* 2012;16:301–311.
171. Hsu CY, Lee YH, Hsia CY, et al. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the Milan criteria. *Ann Surg Oncol* 2013;20:2035–2042.



172. Guglielmi A, Ruzzenente A, Valdegamberi A, et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. *J Gastrointest Surg* 2008;12:192–198.
173. Vivarelli M, Guglielmi A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. *Ann Surg* 2004;240:102–107.
174. Wakai T, Shirai Y, Suda T, et al. Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma < or =4 cm. *World J Gastroenterol* 2006;12:546–552.
175. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. *Ann Surg* 2006;243:321–328.
176. Liang HH, Chen MS, Peng ZW, et al. Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study. *Ann Surg Oncol* 2008;15:3484–3493.
177. Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg* 2010;252:903–912.
178. Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. *J Hepatol* 2012;57:794–802.
179. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology* 2011;140:497–507.
180. Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. *Radiology* 1983;148:397–401.
181. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002;359:1734–1739.
182. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002;35:1164–1171.
183. Becker G, Soezgen T, Olschewski M, et al. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. *World J Gastroenterol* 2005;11:6104–6109.
184. Soliman H, Ringash J, Jiang H, et al. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. *J Clin Oncol* 2013;31:3980–3986.
185. Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. *Int J Radiat Oncol Biol Phys* 1995;31:1237–1248.
186. Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. *Semin Radiat Oncol* 2011;21:256–263.
187. Feng M, Normolle D, Pan CC, et al. Dosimetric analysis of radiation-induced gastric bleeding. *Int J Radiat Oncol Biol Phys* 2012;84:e1–e6.
188. Yoon HI, Koom WS, Lee JJ, et al. The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. *Liver Int* 2012;32:1165–1171.
189. Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. *J Hepatobiliary Pancreat Surg* 2005;12:16–22.
190. Stenmark MH, Cao Y, Wang H, et al. Indocyanine green for individualized assessment of functional liver reserve in patients undergoing liver radiation therapy. *Int J Radiat Oncol Biol Phys* 2013;87:S26–S27.
191. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. *Int J Radiat Oncol Biol Phys* 2002;53:810–821.
192. Robertson JM, McGinn CJ, Walker S, et al. A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. *Int J Radiat Oncol Biol Phys* 1997;39:1087–1092.
193. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. *J Clin Oncol* 2005;23:8739–8747.
194. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. *J Clin Oncol* 2000;18:2210–2218.
195. McGinn CJ, Ten Haken RK, Ensminger WD, et al. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. *J Clin Oncol* 1998;16:2246–2252.
196. Mornex F, Girard N, Beziat C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies—mature results of the French Phase II RTF-1 trial. *Int J Radiat Oncol Biol Phys* 2006;66:1152–1158.
197. Seong J, Lee IJ, Shim SJ, et al. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. *Liver Int* 2009;29:147–152.
198. Shim SJ, Seong J, Han KH, et al. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. *Liver Int* 2005;25:1189–1196.
199. Guo WJ, Yu EX, Liu LM, et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. *World J Gastroenterol* 2003;9:1697–1701.
200. Huang YJ, Hsu HC, Wang CY, et al. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2009;73:1155–1163.
201. Balter JM, Brock KK, Litzenberg DW, et al. Daily targeting of intrahepatic tumors for radiotherapy. *Int J Radiat Oncol Biol Phys* 2002;52:266–271.
202. Balter JM, Dawson LA, Kazanjian S, et al. Determination of ventilatory liver movement via radiographic evaluation of diaphragm position. *Int J Radiat Oncol Biol Phys* 2001;51:267–270.
203. Blomgren H, Lax I, Naslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. *Acta Oncol* 1995;34:861–870.
204. Mendez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. *Acta Oncol* 2006;45:831–837.
205. Tse RV, Hawkins M, Lockwood C, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Clin Oncol* 2008;26:657–664.
206. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. *J Clin Oncol* 2013;31:1631–1639.
207. Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. *Clin Transl Oncol* 2010;12:218–225.
208. Liu E, Stenmark MH, Schipper MJ, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors. *Transl Oncol* 2013;6:442–446.
209. Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. *Acta Oncol* 2014;53:399–404.
210. Bibault JE, Dewas S, Vautravers-Dewas C, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. *PLoS One* 2013;8:e77472.
211. Chiba T, Tokuyue K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. *Clin Cancer Res* 2005;11:3799–3805.
212. Fukumitsu N, Sugahara S, Nakayama H, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2009;74:831–836.
213. Kato H, Tsujii H, Miyamoto T, et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. *Int J Radiat Oncol Biol Phys* 2004;59:1468–1476.
214. Goldschmidt RP, Kotzen JA, Giraud RM. Intraductal hepatocellular carcinoma treated by intraluminal brachytherapy. *Clin Oncol (R Coll Radiol)* 1993;5:118–119.
215. Crellin RP, Chan SY. Hepatocellular carcinoma treated by intraluminal brachytherapy. *Clin Oncol (R Coll Radiol)* 1993;5:332.
216. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. *J Vasc Interv Radiol* 2005;16:205–213.
217. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. *J Vasc Interv Radiol* 2005;16:1627–1639.
218. Sangro B, Salem R, Kennedy A, et al. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. *Am J Clin Oncol* 2011;34:422–431.
219. Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. *J Vasc Interv Radiol* 2007;18:1375–1382.
220. Abou-Alfa GK, Venook AP. The impact of new data in the treatment of advanced hepatocellular carcinoma. *Curr Oncol Rep* 2008;10:199–205.
221. Poon RT, Ho JW, Tong CS, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. *Br J Surg* 2004;91:1354–1360.
222. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res* 2004;64:7099–7109.
223. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. *J Clin Oncol* 2006;24:4293–4300.
224. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008;359:378–390.
225. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009;10:25–34.
226. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. *J Hepatol* 2012;57:821–829.
227. Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. *J Clin Oncol* 2013;31:4067–4075.

228. Lachenmayer A, Alsinet C, Savić R, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. *Clin Cancer Res* 2012;18:4997–5007.
229. Giambartolomei S, Covone F, Levvero M, et al. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. *Oncogene* 2001;20:2606–2610.
230. Himmelsbach K, Sauter D, Baumert TF, et al. New aspects of an antitumour drug: sorafenib efficiently inhibits HCV replication. *Gut* 2009;58:1644–1653.
231. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. *J Clin Oncol* 2009;27:3027–3035.
232. Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. *Lancet Oncol* 2009;10:794–800.
233. Koerberle D, Montemurro M, Samaras P, et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). *Oncologist* 2010;15:285–292.
234. Finn RS, Kang YK, Mulcahy M, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. *Clin Cancer Res* 2012;18:2090–2098.
235. Park JW, Finn RS, Kim JS, et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. *Clin Cancer Res* 2011;17:1973–1983.
236. Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. *J Clin Oncol* 2013;31:3517–3524.
237. Toh HC, Chen PJ, Carr BI, et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. *Cancer* 2013;119:380–387.
238. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. *J Clin Oncol* 2008;26:2992–2998.
239. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. *J Clin Oncol* 2006;24:1898–1903.
240. Hsu CH, Yang TS, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. *Br J Cancer* 2010;102:981–986.
241. Sun W, Sohal D, Haller DG, et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. *Cancer* 2011;117:3187–3192.
242. Kaseb AO, Garrett-Mayer E, Morris JS, et al. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. *Oncology* 2012;82:67–74.
243. Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. *JAMA* 2010;304:2154–2160.
244. Alavi AS, Acevedo L, Min W, et al. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. *Cancer Res* 2007;67:2766–2772.
245. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. *Adv Enzyme Regul* 2006;46:249–279.
246. Hoffmann K, Franz C, Xiao Z, et al. Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma. *Anticancer Res* 2010;30:4503–4508.
247. Zaanan A, Williet N, Hebbbar M, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. *J Hepatol* 2013;58:81–88.
248. Assenat E, Boige V, Thézenas S. Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRÓDIGE 10 trial). Presented at: 2013 ASCO Annual Meeting; 2013; Chicago, IL.
249. Chu JS, Ge FJ, Zhang B, et al. Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma. *J Exp Clin Cancer Res* 2013;32:16.
250. Wang R, Ferrell LD, Faouzi S, et al. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. *J Cell Biol* 2001;153:1023–1034.
251. Heideman DA, Overmeer RM, van Beusechem VW, et al. Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. *Cancer Gene Ther* 2005;12:954–962.
252. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. *Lancet Oncol* 2013;14:55–63.
253. Verslype C, Cohn AL, Kelley RK. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT). Presented at: 2012 ASCO Annual Meeting; 2012; Chicago, IL.
254. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. *Gastroenterology* 2008;135:1972–1983.
255. Zhu AX, Abrams TA, Mksad R, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. *Cancer* 2011;117:5094–5102.
256. Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. *J Clin Oncol* 2013;31:3509–3516.
257. Zhu AX, Finn RS, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. *Clin Cancer Res* 2013;19:6614–6623.
258. Ensor CM, Holtsberg FW, Bomalaski JS, et al. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. *Cancer Res* 2002;62:5443–5450.
259. Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. *J Clin Oncol* 2004;22:1815–1822.
260. Glazer ES, Piccirillo M, Albino V, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. *J Clin Oncol* 2010;28:2220–2226.
261. Yang TS, Lu SN, Chao Y, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. *Br J Cancer* 2010;103:954–960.
262. Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. *Gastrointest Cancer Res* 2011;4:40–44.
263. Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. *Cancer Sci* 2008;99:159–165.
264. Piperdi B, McGuire B, Parvez M, et al. Second interim analysis of GIDEON (Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib): Sorafenib treatment and safety in U.S. patients with Child-Pugh B status. Presented at: 2012 ASCO Annual Meeting; 2012; Chicago, IL.
265. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. *J Clin Oncol* 2009;27:1800–1805.
266. Ringe B, Wittekind C, Weimann A, et al. Results of hepatic resection and transplantation for fibrolamellar carcinoma. *Surg Gynecol Obstet* 1992;175:299–305.
267. Soreide O, Czerniak A, Bradpiece H, et al. Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and a review of the literature. *Am J Surg* 1986;151:518–523.
268. Ruffin MT. Fibrolamellar hepatoma. *Am J Gastroenterol* 1990;85:577–581.
269. Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. *Hepatology* 1997;26:877–883.
270. El-Gazzaz G, Wong W, El-Hadary MK, et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. *Transpl Int* 2000;13:S406–S409.
271. Ang CS, Kelley RK, Choti MA, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. *Gastrointest Cancer Res* 2013;6:3–9.
272. Cruz RJ Jr, Ranganathan S, Mazariegos G, et al. Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: new trends and future opportunities. *Surgery* 2013;153:150–159.
273. Makhoulouf HR, Ishak KG, Goodman ZD. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. *Cancer* 1999;85:562–582.